Complete Genomics is a life sciences company that has developed and commercialized a deoxyribonucleic acid sequencing platform for whole human genome sequencing and analysis. Co.'s Complete Genomics Analysis Platform Platform, combines its human genome sequencing technology with its informatics and data management software and its outsourced service model to provide its customers with data that is ready to be used for genome-based research. Co. sells its whole human genome sequencing service through its direct field sales and support organizations. The GNOM average annual return since 2019 is shown above.
The Average Annual Return on the GNOM average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GNOM average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GNOM average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|